Gastrointestinal Cancers

12 protocols meet the specified criteria.
  • A021502

    Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • A021703

    Randomized Double-Blind, Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
  • APL-101-01

    Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation
  • COG-AHEP1531

    COG-AHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
  • D933GC00001

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
  • DB-020-002

    Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
  • EA2165

    A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • EAY131

    Molecular Analysis for Therapy Choice (MATCH)
  • INCB54828-207

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
  • NETSPOT

    A Comparison of NETSPOT Imaging Versus 18F-FDG-PET/CT in Head and Neck Cancer Patients
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.
  • TIGER-PAC

    Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer